Trial Information
Prospective, Observational Safety Study of Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Treated With Rituximab
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), according
to Chapel Hill Consensus Conference Definitions for MPA and ACR Criteria for the
Classification of GPA
- Disease severity requiring rituximab treatment per the investigator's assessment
Exclusion Criteria:
- Prior use of rituximab (except if received within 4 weeks of screening)
- Known hypersensitivity to rituximab, to any component of the product, or to murine
proteins
- Pregnant or breastfeeding women
- Diagnosis of Churg-Strauss syndrome
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Safety: Incidence of serious infections (infections that are serious adverse events [SAEs] or non-SAE infections treated with iv antimicrobials)
Outcome Time Frame:
approximately 6 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Genentech
Authority:
United States: Food and Drug Administration
Study ID:
WA27893
NCT ID:
NCT01613599
Start Date:
June 2012
Completion Date:
April 2018
Related Keywords:
- Wegener's Granulomatosis, Microscopic Polyangiitis
- Wegener Granulomatosis
- Systemic Vasculitis
- Microscopic Polyangiitis
Name | Location |
|
Hinsdale, Illinois 60521 |
|
Alexandria, Minnesota 56308 |
|
Phoenix, Arizona 85012 |
|
Fountain Valley, California 92708 |
|
Miami, Florida 33176 |
|
Albany, New York 12208 |
|
Cleveland, Ohio 44195 |
|
Philadelphia, Pennsylvania 19104 |
|
Boston, Massachusetts |
|
Charlotte, North Carolina |
|
Salt Lake City, Utah 84112 |